Primary outcome
[대역어] None
[용어속성] Term
[용어속성] Term
COVID-19 and the injured patient: A multicenter review
Research article
[키워드] adverse events
Affect
age
Analysis
baseline characteristics
C-reactive protein
Coagulopathy
Cohort
collected
Comorbidities
composed
Coronavirus disease 2019
COVID-19
cumulative
D-dimer
demographics
diabetes
events
ferritin
Frame
Hospitalization
hypertension
In-hospital death
Injury
ISS
Kaplan–Meier method
log-rank test
median
morbidity and mortality
Mortality
multicenter
neurologic
New York
Older
outcome
outcomes
Patient
patients
performed
physiological
Primary outcome
Result
Retrospective analysis
severity
shown
study period
surgical
tested
trauma
trauma patient
trauma patients
were excluded
were used
[DOI] 10.1016/j.jss.2022.06.068 [Article Type] Research article
[DOI] 10.1016/j.jss.2022.06.068 [Article Type] Research article
Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients
Article
[키워드] 95% CI
95% confidence interval
adjusted odds ratio
Administered
age
Characteristics
clinical trial
Comorbidity
COVID-19
COVID-19 outpatient
death
defined
died
early symptomatic COVID-19
effective
Electronic health record
health system
Hospitalization
Hospitalized
immunocompromised status
lack
mAb
mAbs
Male sex
Mild
monoclonal antibodies
monoclonal antibody
monoclonal antibody treatment
Mortality
mortality data
multicenter
Neutralizing
obesity
Observational cohort study
occurred
pandemic
Patient
patients
patients with COVID-19
positive
Primary outcome
real-world data
reducing
SARS-CoV-2
SARS-CoV-2 test
SARS-CoV-2 vaccination
SARS-CoV-2.
Treatment
Vaccine
variants
while
[DOI] 10.1186/s12879-022-07819-z PMC 바로가기
[DOI] 10.1186/s12879-022-07819-z PMC 바로가기
Efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia: a phase 2, randomized, double-blind, placebo-controlled trial
Article
[키워드] 1:1
Administered
administration
adverse event
age
Analysis
animal model
Anti-inflammatory
assigned
baseline
Borg
change
changes in
Chronic diseases
clinical trial
clinically
COVID
COVID pneumonia
COVID-19
defined
Diagnosis
discharged
double-blind
Dyspnea
Effect
effective
Efficacy
Endpoint
enrolled
evaluated
female
female gender
FEV
first symptom
FVC
impairment
increase in
indicated
Infection
initial
LLC
lung damage
Lung fibrosis
Lung function
Lungs
mMRC
moderate
NCT04527354
offer
past medical history
Patient
patients
pharmacological treatment
Placebo
placebo group
placebo-controlled clinical trial
placebo-controlled trial
Post-COVID rehabilitation
predicted
Prevent
Primary outcome
proportion
pulmonary dysfunction
pulmonary fibrosis
Pulmonary function
questionnaire
Randomized
Randomly
reduction in
Registered
rehabilitation
risk factor
Russia
SARS-CoV-2
secondary
shown
significant decrease
significant difference
stratified
Support
Symptoms
Tolerability
Treamid.
Treatment
Trial
was done
women
[DOI] 10.1186/s12967-022-03660-9 PMC 바로가기
[DOI] 10.1186/s12967-022-03660-9 PMC 바로가기
Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19
Article
[키워드] 30-Day mortality
Administered
administration
adverse event
adverse events
analysed
Biomarker
C-reactive protein
clinical
Clinical improvement
cohorts of patient
comparable
complementary
Complementary therapies
coronavirus disease
COVID-19
Critical
Critical care
decrease
Efficacy
epidemiologically
group
hospitalised
Hypothesis
inflammatory parameters
knowledge
lactate dehydrogenase
medication
Mortality
onset of symptom
outcome
Patient
patients with COVID-19
pharmacological treatment
Pneumonia
Primary outcome
pulmonary medicine
Quotient
radiological
radiological improvement
Radiology.
randomised controlled trial
reductions in
SaO_{2}
secondary
Severe COVID-19 pneumonia
statistically significant difference
subgroup
subgroups
the timing
therapy
Tocilizumab
tocilizumab administration
two group
were recorded
while
[DOI] 10.1136/ejhpharm-2020-002669 PMC 바로가기
[DOI] 10.1136/ejhpharm-2020-002669 PMC 바로가기
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study
Article
[키워드] adjusted
age
All participant
anti-SARS-CoV-2
anti-TNF
antibody
Antibody binding
antibody concentration
Antibody concentrations
approved
available data
boost
booster
case-control study
combination therapy
Concentration
control group
COVID-19
COVID-19 vaccine
Diagnosis
disease
dose
Evidence
first dose
geometric mean
geometric mean ratio
group
groups
had no
healthy control
healthy individuals
heterologous vaccine
homologous
IBD
Immunosuppressed
immunosuppressed patient
immunosuppressive
Immunosuppressive treatment
Infection
Inflammatory bowel disease
jak inhibitors
multicentre
multivariable
nine
no significant difference
Older
Older age
participant
Patient
patients treated
Pfizer
Primary outcome
receiving
Receptor binding domain
recipient
recruited
reduced
regimen
response
S1 RBD
SARS-COV-2 infection
SARS-CoV-2 spike
SARS-CoV-2 vaccination
significantly
significantly lower
Support
T-cell Response
T-cell responses
the healthy
therapy
Tofacitinib
Treatment
ulcerative colitis
Vaccine
vaccine dose
vaccine doses
vaccine-induced antibody response
VIP
were measured
[DOI] 10.1016/S2468-1253(22)00274-6 PMC 바로가기
[DOI] 10.1016/S2468-1253(22)00274-6 PMC 바로가기
Efficacy and safety of nitazoxanide in treating SARS-CoV-2 infection: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials
Article
[키워드] 95% CI
95% confidence interval
addition
anti-inflammatory effect
antiparasitic
antiviral activity
blinded
clinical benefit
continuous variable
COVID-19
D-dimer
D-dimer level
death
dichotomous variable
Disease progression
Effect
effect size
Efficacy and safety
element
eligibility
enrolled
Evidence
Frequency
ICU admission
in vitro
individual
Inflammation
Invasive mechanical ventilation
lactate dehydrogenase
LDH
magnitude
Meta-analysis
Mild
moderate
Moderate COVID-19
nitazoxanide
no difference
Patient
patients
peer-reviewed
performed
Placebo
placebo-controlled
positive
positive RT-PCR
Primary outcome
randomized clinical trial
RCT
RCTs
receiving
reducing
reduction in
reported
risk
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 infection.
secondary outcome
serum biomarker
SMD
standardized mean difference
systematic review
tested
to define
treat
treated
Viral load
WBC
were used
White blood cell
with COVID-19
[DOI] 10.1007/s00228-022-03380-5 PMC 바로가기
[DOI] 10.1007/s00228-022-03380-5 PMC 바로가기
Bamlanivimab Use in a Military Treatment Facility
Article
[키워드] acute respiratory syndrome
Administered
administration
Admission
analyzed
approval
approved
Arm
bamlanivimab
Care
caused
cohort study
coronavirus
coronavirus disease
COVID-19
COVID-19 patient
death
declined
diagnosed
Disease progression
facility
FDA
Follow-up
Guidance
help
hospital
Hospital admission
Hospitalization
information
initial
inpatient admission
institutional review board
intravenous
IRB
lack
Mild-to-moderate
monoclonal antibody
Patient
patients
patients with SARS-CoV-2
placebo group
Prevent
Primary outcome
progression
provided
receiving
replicated
reported
required
retrospective
risk
risk factor
SARS-CoV-2
secondary outcome
self-reported symptom
severe COVID-19
small sample size
Spread
statistical significance
statistically significant
Study design
Symptom
treated
Treatment
treatment group
virus-neutralizing
was obtained
were given
Wuhan, China
[DOI] 10.1093/milmed/usab188 PMC 바로가기
[DOI] 10.1093/milmed/usab188 PMC 바로가기
Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19
Article
[키워드] 95% CI
Administered
administration
Adverse
affected
analysed
antiviral therapy
Antiviral treatment
ARMS
baseline
changed
Combination
combination therapy
concentrations
conducted
coronavirus 2
COVID-19
COVID-19 pandemic
Day
Dose escalation
doses
double-blind
double-blind trial
drug level
effective
Efficacy
evaluate the effect
event
Favipiravir
healthy
Interaction
Lopinavir-ritonavir
measure
monotherapy
Odds ratio
Outpatient
participant
Participants
Phase 2
Placebo
placebo-controlled
placebo-controlled trial
placebos
plasma
primary analysis
Primary outcome
provided
randomised
recruited
reduced
respiratory
SARS-CoV-2
SARS-CoV-2 viral load
significant interaction
significantly
study population
symptom onset
the mean
trajectory
Treatment
undetectable
United Kingdom
Viral load
virus
[DOI] 10.1371/journal.pmed.1004120 PMC 바로가기
[DOI] 10.1371/journal.pmed.1004120 PMC 바로가기
Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial
Article
[키워드] 95% CI
benefit
confidence interval
COVID-19
COVID-19 infection
Effect
Evidence
fatigue
Finnish
Follow-up
Hospitalization
hospitalized patients
hospitals
joint
long-COVID
Long-term follow-up
memory
occurred
outcome
Pain
Patient
Primary outcome
problem
Quality of life
Randomized
randomized trial
recruited
Remdesivir
reported
resulting
SOC
Standard of care
survived
Symptom
Symptoms
Trial
[DOI] 10.1038/s41467-022-33825-5 PMC 바로가기
[DOI] 10.1038/s41467-022-33825-5 PMC 바로가기